Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Richter Gedeon Vegyeszeti Gyar Rt

Gyogyszerkutato Inteezet/pharmaceutical Research Institute

Tibor Horvath

Agoston David

Endre Csanyi

Sandor Virag

Gabor Nagy

Lajos Toldy

Katalin Marmarosi Nee Kellner

Janos Borvendeg

Sandor Eckhardt

Kalman Simon

Emilia Kiraly Nee Vida

Csaba Kiss

Eva Kiss

Gizella Abraham

Agnes Udvardy

Ilona Simonidesz Nee Vermes

Agnes Udvardi

Ilona S Nee Hermann

Magdolna Vitanyi Nee Morvai

Ferenc Levai

Gabor Szekacs

Laszlo Miszkiewicz

Laszlo Prezmeczky

Gusztav Klenk

Erzsebet Englovszky

The invention relates to a combination useful for the substitution of bone defects having pathologically developed or being artificially established as well as compositions containing these combinations. The combinations of the invention preferably contain in a weight ratio of 1:9 to 9:1, most preferably 1:1 porous hydroxylapatite and/or tricalcium phosphate in relation to 7-isopropoxyisoflavone.

Pharmaceutical bone growth-promoting composition and process

A novel 1,1,2-triphenylpropene derivative, namely: ##STR1## acts on the endocrine system of rats. It exerts oestrogenic or antioestrogenic effects of varying strength in rats, and furthermore inhibits the growth of the mammary tumor induced by 7,12-dimethyl-benz(a)anthracene in rats.

1,1,2-triphenylpropane and -propene derivatives

Time-release pharmaceutical compositions, suitable for oral administration, are disclosed, which comprise as active ingredient 50 to 70% by weight of a compound of the formula (I) ##STR1## or the formula (Ia) ##STR2## wherein R is hydrogen or --CH.sub.2 COOH,

Time-release

The invention relates to stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and a process for the preparation thereof. The tablets according to the invention comprise 0.2 to 20% by weight of one or more natural or synthetic prostaglandins, 0.4 to 40% by weight of a non-toxic buffer, which adjusts the pH of the liquid film formed on the surface of the solid phase due to air humidity, to 3 to 5, 1 to 50% by weight of stearic acid, 0 to 15% by weight of an alkali earth metal stearate, 10 to 95% by weight of lactose and/or mannite, 0 to 15% by weight of a further granulation aid, 1 to 30% by weight of a disintegrating agent and optionally 0.5 to 10% by weight of a flavoring and aroma substance and are prepared under a pressure of 500 to 2000 kp./cm.sup.2. (49.03 to 196.13 MPa).

Stabilized, prostaglandin-containing tablets with controlled rate of

The invention relates to bis(nitrosoureido)-polyol derivatives of general formula I

Bis(nitrosoureido)-polyol derivatives

Growing community of inventors

Budapest, Hungary

Tibor Horvath